Hao Kun, Li Xingpeng, Ren Jie, Yu Chunkai, Zhang Li, Li Bin, Wang Rengui, Shen Wenbin, Sun Yuguang
Department of Lymphatic Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China.
Department of Medical Imaging, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China.
Oncol Lett. 2025 Sep 9;30(5):516. doi: 10.3892/ol.2025.15262. eCollection 2025 Nov.
Lymphedema, which is characterized by impaired lymphatic drainage leading to tissue swelling, represents a relatively uncommon clinical entity, with an estimated prevalence of <1% being observed in the general population. Although most cases arise from postsurgical complications or filariasis, lymphoma-associated lymphedema remains an exceedingly rare manifestation, with only 19 cases documented in the medical literature prior to the present study. The current study presented a case series of 11 patients with histologically confirmed lymphoma manifesting with lymphedema, which represents the largest single-center report to date. In the present cohort spanning a time period from 2007-2024, patients who initially presented with refractory lymphedema (9 lower extremity cases, 1 upper extremity case and 1 systemic case) subsequently received a diagnosis of lymphoma via comprehensive evaluation, including imaging (100% detection rate on CT/MRI) and histopathology examinations. The median latency from edema onset to lymphoma diagnosis was 7 months (range, 1-24 months), with 72.7% (8 out of 11) of the patients demonstrating B-cell lineage predominance. The present case series underscored the notion that although lymphedema secondary to lymphoma constitutes <0.5% of all secondary lymphedema cases, it warrants consideration in patients with atypical presentations, such as rapid progression (54.5%), systemic symptoms (81.8%) or abnormal tumor markers (66.7%). The present case report findings emphasized the idea that lymphoma should be included in the differential diagnosis of unexplained lymphedema, particularly when accompanied by warning signs such as lymphadenopathy (100% imaging positivity) or hematologic abnormalities (45.5% anemia prevalence).
淋巴水肿的特征是淋巴引流受损导致组织肿胀,是一种相对不常见的临床病症,在普通人群中的估计患病率<1%。虽然大多数病例源于术后并发症或丝虫病,但淋巴瘤相关的淋巴水肿仍然是一种极其罕见的表现,在本研究之前的医学文献中仅记录了19例。本研究报告了一组11例经组织学确诊的淋巴瘤患者,这些患者表现为淋巴水肿,这是迄今为止最大的单中心报告。在本队列中,时间跨度为2007年至2024年,最初表现为难治性淋巴水肿的患者(9例下肢病例、1例上肢病例和1例全身病例)随后通过包括影像学(CT/MRI检测率100%)和组织病理学检查在内的综合评估被诊断为淋巴瘤。从水肿开始到淋巴瘤诊断的中位潜伏期为7个月(范围1至24个月),72.7%(11例中的8例)的患者表现为B细胞系占优势。本病例系列强调,尽管淋巴瘤继发的淋巴水肿占所有继发性淋巴水肿病例的比例<0.5%,但对于具有非典型表现的患者,如快速进展(54.5%)、全身症状(81.8%)或肿瘤标志物异常(66.7%),仍需考虑。本病例报告结果强调,淋巴瘤应纳入不明原因淋巴水肿的鉴别诊断,特别是当伴有如淋巴结病(影像学阳性率100%)或血液学异常(贫血患病率45.5%)等警示信号时。